{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:26:54Z","timestamp":1790177214096,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5611,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.nurt.2008.01.003","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T09:42:40Z","timestamp":1207129360000},"page":"226-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Neuroprotection for Huntington\u2019s Disease: Ready, Set, Slow"],"prefix":"10.1016","volume":"5","author":[{"given":"Steven M.","family":"Hersch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Diana","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.01.003_bib1","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1073\/pnas.0408936102","article-title":"A potent small molecule inhibits polyglutamine aggregation in Huntington\u2019s disease neurons and suppresses neurodegeneration in vivo","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib2","doi-asserted-by":"crossref","first-page":"16685","DOI":"10.1073\/pnas.0707842104","article-title":"A small-molecule therapeutic lead for Huntington\u2019s disease: preclinical pharmacology and efficacy of C2-8 in the R6\/2 transgenic mouse","volume":"104","author":"Chopra","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib3","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of the Huntington\u2019s disease mutation: the sensitivity and specificity of measuring CAG repeats","volume":"330","author":"Kremer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2008.01.003_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/ng1093-168","article-title":"De novo expansion of a (CAG)n repeat in sporadic Huntington\u2019s disease","volume":"5","author":"Myers","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ng1093-174","article-title":"Molecular analysis of new mutations for Huntington\u2019s disease: intermediate alleles and sex of origin effects","volume":"5","author":"Goldberg","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/mds.20589","article-title":"No going home for hospitalized Huntington\u2019s disease patients","volume":"20","author":"Dubinsky","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.003_bib7","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington\u2019s disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nurt.2008.01.003_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14656566.8.2.141","article-title":"A systematic review of the treatment studies in Huntington\u2019s disease since 1990","volume":"8","author":"Bonelli","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nurt.2008.01.003_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1602\/neurorx.1.3.298","article-title":"Translating therapies for Huntington\u2019s disease from genetic animal models to clinical trials","volume":"1","author":"Hersch","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.nurt.2008.01.003_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrn1386","article-title":"Experimental therapeutics in transgenic mouse models of Huntington\u2019s disease","volume":"5","author":"Beal","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib11","series-title":"Current therapy in neurologic disease","first-page":"275","article-title":"Huntington\u2019s Disease","author":"Hersch","year":"1997"},{"key":"10.1016\/j.nurt.2008.01.003_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11920-996-0030-2","article-title":"An overview of psychiatric symptoms in Huntington\u2019s disease","volume":"3","author":"Anderson","year":"2001","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.nurt.2008.01.003_bib13","series-title":"A physician\u2019s guide to the management of Huntington\u2019s Disease","author":"Rosenblatt","year":"1999"},{"key":"10.1016\/j.nurt.2008.01.003_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.brainresbull.2006.10.022","article-title":"Late stage care in Huntington\u2019s disease","volume":"72","author":"Simpson","year":"2007","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.nurt.2008.01.003_bib15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1176\/appi.psy.48.5.400","article-title":"The impact of Huntington\u2019s disease on family life","volume":"48","author":"Vamos","year":"2007","journal-title":"Psychosomatics"},{"key":"10.1016\/j.nurt.2008.01.003_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.nurt.2008.01.003_bib17","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1523\/JNEUROSCI.11-12-03877.1991","article-title":"Proliferative and degenerative changes in striatal spiny neurons in Huntington\u2019s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry","volume":"11","author":"Ferrante","year":"1991","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib18","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1212\/WNL.43.10.2088","article-title":"Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington\u2019s disease: a quantitative Golgi study","volume":"43","author":"Sotrel","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib19","series-title":"Movement disorders: neurologic principles and practice","first-page":"503","article-title":"Neuropathology and pathophysiology of Huntington\u2019s disease","author":"Hersch","year":"1997"},{"key":"10.1016\/j.nurt.2008.01.003_bib20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.58.5.695","article-title":"Regional and progressive thinning of the cortical ribbon in Huntington\u2019s disease","volume":"58","author":"Rosas","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1212\/01.wnl.0000174432.87383.87","article-title":"Regional cortical thinning in preclinical Huntington disease and its relationship to cognition","volume":"65","author":"Rosas","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archneur.1996.00550120105023","article-title":"Basal ganglia volume and proximity to onset in presymptomatic Huntington disease","volume":"53","author":"Aylward","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P","article-title":"Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington\u2019s disease","volume":"15","author":"Aylward","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.003_bib24","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1073\/pnas.0504921102","article-title":"Genome-wide expression profiling of human blood reveals biomarkers for Huntington\u2019s disease","volume":"102","author":"Borovecki","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B","article-title":"Quantitative neuropathological changes in presymptomatic Huntington\u2019s disease","volume":"49","author":"G\u00f3mez-Tortosa","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib26","first-page":"1715","article-title":"fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington\u2019s disease","volume":"25","author":"Paulsen","year":"2004","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.nurt.2008.01.003_bib27","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ana.20121","article-title":"Functional brain changes in presymptomatic Huntington\u2019s disease","volume":"55","author":"Reading","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.20979","article-title":"Diffusion tensor imaging in presymptomatic and early Huntington\u2019s disease: selective white matter pathology and its relationship to clinical measures","volume":"21","author":"Rosas","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.003_bib29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneur.63.7.991","article-title":"At risk for Huntington disease: the PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled","volume":"63","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainresbull.2006.10.028","article-title":"Change in MRI striatal volumes as a biomarker in preclinical Huntington\u2019s disease","volume":"72","author":"Aylward","year":"2007","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.nurt.2008.01.003_bib31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jnnp.2006.103309","article-title":"Psychiatric disorders in preclinical Huntington\u2019s disease","volume":"78","author":"Julien","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.003_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/archneur.64.1.116","article-title":"Specific psychiatric manifestations among preclinical Huntington disease mutation carriers","volume":"64","author":"Marshall","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib33","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","article-title":"Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the Predict-HD Study","volume":"62","author":"Duff","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.003_bib34","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00415-007-0611-y","article-title":"Oxidative stress parameters in plasma of Huntington\u2019s disease patients, asymptomatic Huntington\u2019s disease gene carriers and healthy subjects: a cross-sectional study","volume":"254","author":"Klepac","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/mds.20373","article-title":"Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington\u2019s disease","volume":"20","author":"Saft","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.003_bib36","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1096\/fj.03-0079fje","article-title":"Aberrant A2A receptor function in peripheral blood cells in Huntington\u2019s disease","volume":"17","author":"Varani","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.nurt.2008.01.003_bib37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archneur.63.6.883","article-title":"Preparing for preventive clinical trials: the Predict-HD study","volume":"63","author":"Paulsen","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib39","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1212\/01.wnl.0000261918.90053.96","article-title":"Predictors of diagnosis in Huntington disease","volume":"68","author":"Langbehn","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib40","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/0140-6736(92)92610-R","article-title":"Understanding the low uptake of presymptomatic DNA testing for Huntington\u2019s disease","volume":"340","author":"Tibben","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2008.01.003_bib41","article-title":"Perceptions of discrimination among persons who have undergone predictive testing for Huntington\u2019s disease","author":"Penziner","year":"2007","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1179\/hrge.11.2.e35336gt18776032","article-title":"Ethical issues and policy analysis for genetic testing: Huntington\u2019s disease as a paradigm for diseases with a late onset","volume":"11","author":"Lilani","year":"2005","journal-title":"Hum Reprod Genet Ethics"},{"key":"10.1016\/j.nurt.2008.01.003_bib43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pec.2006.08.009","article-title":"To know or not to know: a review of behaviour and suicidal ideation in preclinical Huntington\u2019s disease","volume":"65","author":"Robins Wahlin","year":"2007","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.nurt.2008.01.003_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1037\/0278-6133.23.2.189","article-title":"Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7\u201310 years after the test","volume":"23","author":"Timman","year":"2004","journal-title":"Health Psychol"},{"key":"10.1016\/j.nurt.2008.01.003_bib45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","article-title":"Rate of functional decline in Huntington\u2019s disease","volume":"54","author":"Marder","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","article-title":"A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1176\/jnp.2007.19.3.310","article-title":"Longitudinal evaluation of \u201cpresymptomatic\u201d carriers of Huntington\u2019s disease","volume":"19","author":"Witjes-An\u00e9","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib48","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0896-6273(95)90346-1","article-title":"Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons","volume":"14","author":"DiFiglia","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.nurt.2008.01.003_bib49","doi-asserted-by":"crossref","first-page":"7674","DOI":"10.1523\/JNEUROSCI.18-19-07674.1998","article-title":"The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human","volume":"18","author":"Gutekunst","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib50","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF03401575","article-title":"Normal and expanded Huntington\u2019s disease gene alleles produce distinguishable proteins due to translation across the CAG repeat","volume":"1","author":"Persichetti","year":"1995","journal-title":"Mol Med"},{"key":"10.1016\/j.nurt.2008.01.003_bib51","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0896-6273(95)90345-3","article-title":"Widespread expression of Huntington\u2019s disease gene (IT15) protein product","volume":"14","author":"Sharp","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.nurt.2008.01.003_bib52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ng0595-104","article-title":"Cellular localization of the Huntington\u2019s disease protein and discrimination of the normal and mutated form","volume":"10","author":"Trottier","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0166-2236(00)01721-5","article-title":"Loss of normal huntingtin function: new developments in Huntington\u2019s disease research","volume":"24","author":"Cattaneo","year":"2001","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib54","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington\u2019s disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.01.003_bib56","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ng0896-442","article-title":"Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract","volume":"13","author":"Goldberg","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib57","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1750-3639.1997.tb00897.x","article-title":"Toward understanding the molecular pathology of Huntington\u2019s disease","volume":"7","author":"Wellington","year":"1997","journal-title":"Brain Pathol"},{"key":"10.1016\/j.nurt.2008.01.003_bib58","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1523\/JNEUROSCI.22-18-07862.2002","article-title":"Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington\u2019s disease","volume":"22","author":"Wellington","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2005.03348.x","article-title":"Purification of neuronal inclusions of patients with Huntington\u2019s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers","volume":"95","author":"Hoffner","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.nurt.2008.01.003_bib60","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.nurt.2008.01.003_bib61","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1371\/journal.pgen.0030082","article-title":"Huntingtin interacting proteins are genetic modifiers of neurodegeneration","volume":"3","author":"Kaltenbach","year":"2007","journal-title":"PLoS Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib62","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington\u2019s disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nurt.2008.01.003_bib63","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2006.10.023","article-title":"PGC-1\u03b1, a new therapeutic target in Huntington\u2019s disease?","volume":"127","author":"McGill","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.nurt.2008.01.003_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2005.04.008","article-title":"The therapeutic role of creatine in Huntington\u2019s disease","volume":"108","author":"Ryu","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nurt.2008.01.003_bib65","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1089\/ars.2006.8.2061","article-title":"Oxidative damage in Huntington\u2019s disease pathogenesis","volume":"8","author":"Browne","year":"2006","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.nurt.2008.01.003_bib66","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.chembiol.2006.05.012","article-title":"Discovery of bioactive small-molecule inhibitor of poly ADP-ribose polymerase: implications for energy-deficient cells","volume":"13","author":"Altmann","year":"2006","journal-title":"Chem Biol"},{"key":"10.1016\/j.nurt.2008.01.003_bib67","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature05778","article-title":"OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells","volume":"447","author":"Kovtun","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.nurt.2008.01.003_bib68","doi-asserted-by":"crossref","first-page":"12908","DOI":"10.1523\/JNEUROSCI.4318-07.2007","article-title":"Neuroprotective effects of synaptic modulation in Huntington\u2019s disease R6\/2 mice","volume":"27","author":"Stack","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1523\/JNEUROSCI.23-03-00961.2003","article-title":"Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington\u2019s disease","volume":"23","author":"Cepeda","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib70","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00415-006-0198-8","article-title":"Apoptotic cascades as possible targets for inhibiting cell death in Huntington\u2019s disease","volume":"253","author":"Pattison","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib71","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.nurt.2008.01.003_bib72","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.01.003_bib73","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib74","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/hmg\/10.10.1049","article-title":"Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release","volume":"10","author":"Jana","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib75","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nchembio883","article-title":"Small molecules enhance autophagy and reduce toxicity in Huntington\u2019s disease models","volume":"3","author":"Sarkar","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.nurt.2008.01.003_bib76","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11910-007-0068-5","article-title":"Autophagy and neurodegeneration","volume":"7","author":"Ventruti","year":"2007","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nurt.2008.01.003_bib77","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4161\/auto.4898","article-title":"Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington\u2019s disease models and enhance killing of mycobacteria by macrophages","volume":"3","author":"Floto","year":"2007","journal-title":"Autophagy"},{"key":"10.1016\/j.nurt.2008.01.003_bib78","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1083\/jcb.200510065","article-title":"Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway","volume":"172","author":"Yamamoto","year":"2006","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nurt.2008.01.003_bib79","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.mam.2006.08.008","article-title":"Role of autophagy in the clearance of mutant huntingtin: a step towards therapy?","volume":"27","author":"Ravikumar","year":"2006","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.nurt.2008.01.003_bib80","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1371\/journal.pone.0000238","article-title":"Proteasome activator enhances survival of Huntington\u2019s disease neuronal model cells","volume":"2","author":"Seo","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nurt.2008.01.003_bib81","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nature06022","article-title":"Global changes to the ubiquitin system in Huntington\u2019s disease","volume":"448","author":"Bennett","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.nurt.2008.01.003_bib82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2121-8-32","article-title":"Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation","volume":"8","author":"Howard","year":"2007","journal-title":"BMC Cell Biol"},{"key":"10.1016\/j.nurt.2008.01.003_bib83","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1523\/JNEUROSCI.4278-06.2007","article-title":"Widespread disruption of repressor element-1 silencing transcription factor\/neuron-restrictive silencer factor occupancy at its target genes in Huntington\u2019s disease","volume":"27","author":"Zuccato","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib84","doi-asserted-by":"crossref","first-page":"11758","DOI":"10.1523\/JNEUROSCI.2461-07.2007","article-title":"Expression profiling of Huntington\u2019s disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration","volume":"27","author":"Strand","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.phrs.2005.01.001","article-title":"Progressive loss of BDNF in a mouse model of Huntington\u2019s disease and rescue by BDNF delivery","volume":"52","author":"Zuccato","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.nurt.2008.01.003_bib86","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1523\/JNEUROSCI.0037-07.2007","article-title":"Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington\u2019s disease by increasing tubulin acetylation","volume":"27","author":"Dompierre","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib87","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/01.wco.0000084229.82329.03","article-title":"Huntington\u2019s disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation","volume":"16","author":"Hersch","year":"2003","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib88","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/hmg\/11.23.2905","article-title":"Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells","volume":"11","author":"Yang","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib89","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/hmg\/ddh175","article-title":"Nuclear-targeting of mutant huntingtin fragments produces Huntington\u2019s disease-like phenotypes in transgenic mice","volume":"13","author":"Schilling","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib90","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/hmg\/8.9.1647","article-title":"Aberrant interactions of transcriptional repressor proteins with the Huntington\u2019s disease gene product, huntingtin","volume":"8","author":"Boutell","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib91","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","article-title":"Sp1 and TAFII130 transcriptional activity disrupted in early Huntington\u2019s disease","volume":"296","author":"Dunah","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.01.003_bib92","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1073\/pnas.98.4.1811","article-title":"The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington\u2019s disease pathogenesis","volume":"98","author":"Holbert","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib93","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nurt.2008.01.003_bib94","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.nurt.2008.01.003_bib95","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington\u2019s disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib96","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/9.14.2197","article-title":"CREB-binding protein sequestration by expanded polyglutamine","volume":"9","author":"McCampbell","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib97","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","article-title":"Histones associated with downregulated genes are hypo-acetylated in Huntington\u2019s disease models","volume":"16","author":"Sadri-Vakili","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib98","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","article-title":"Modulation of nucleosome dynamics in Huntington\u2019s disease","volume":"16","author":"Stack","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nurt.2008.01.003_bib99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pneurobio.2007.02.005","article-title":"Drug targeting of dysregulated transcription in Huntington\u2019s disease","volume":"83","author":"Kazantsev","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nurt.2008.01.003_bib100","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ncpneuro0199","article-title":"Mechanisms of disease: histone modifications in Huntington\u2019s disease","volume":"2","author":"Sadri-Vakili","year":"2006","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib101","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrn1989","article-title":"Histone deacetylase inhibitors as therapeutics for polyglutamine disorders","volume":"7","author":"Butler","year":"2006","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib102","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib103","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.gt.3302664","article-title":"RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases","volume":"13","author":"Denovan-Wright","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.nurt.2008.01.003_bib104","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ymthe.2005.04.003","article-title":"Intrabody applications in neurological disorders: progress and future prospects","volume":"12","author":"Miller","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.nurt.2008.01.003_bib105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1087057107299428","article-title":"Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments","volume":"12","author":"Coufal","year":"2007","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.nurt.2008.01.003_bib106","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/1073858405280639","article-title":"The ubiquitin-proteasome system in Huntington\u2019s disease","volume":"11","author":"Valera","year":"2005","journal-title":"Neuroscientist"},{"key":"10.1016\/j.nurt.2008.01.003_bib107","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-0-387-39975-1_15","article-title":"The stress of misfolded proteins: C. elegans models for neurodegenerative disease and aging","volume":"594","author":"Brignull","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.nurt.2008.01.003_bib108","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib109","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","article-title":"Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington\u2019s disease","volume":"8","author":"Andreassen","year":"2001","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.nurt.2008.01.003_bib110","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib111","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.1085","article-title":"Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington\u2019s disease","volume":"50","author":"Andreassen","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib112","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1097\/00001756-200110290-00044","article-title":"Lipoic acid improves survival in transgenic mouse models of Huntington\u2019s disease","volume":"12","author":"Andreassen","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.nurt.2008.01.003_bib113","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.nurt.2008.01.003_bib114","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington\u2019s disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib115","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1073\/pnas.96.13.7388","article-title":"Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington\u2019s disease brain nuclei","volume":"96","author":"Karpuj","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib116","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1073\/pnas.0502177102","article-title":"Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington\u2019s disease mouse model","volume":"102","author":"Nguyen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib117","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1196\/annals.1306.025","article-title":"Ironing iron out in Parkinson\u2019s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28","volume":"1012","author":"Youdim","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nurt.2008.01.003_bib118","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib119","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington\u2019s disease (HD)","volume":"14","author":"Rosas","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.003_bib120","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.20075","article-title":"Paroxetine retards disease onset and progression in Huntingtin mutant mice","volume":"55","author":"Duan","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.003_bib121","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib122","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib123","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1523\/JNEUROSCI.2599-04.2004","article-title":"Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington\u2019s disease","volume":"24","author":"Ferrante","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.003_bib124","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nurt.2008.01.003_bib125","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","article-title":"Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington\u2019s disease","volume":"99","author":"Keene","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.003_bib126","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","article-title":"Role of brain-derived neurotrophic factor in Huntington\u2019s disease","volume":"81","author":"Zuccato","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nurt.2008.01.003_bib127","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","article-title":"A controlled trial of idebenone in Huntington\u2019s disease","volume":"11","author":"Ranen","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.003_bib128","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1176\/ajp.152.12.1771","article-title":"Trial of d-alpha-tocopherol in Huntington\u2019s disease","volume":"152","author":"Peyser","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.003_bib129","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1212\/WNL.50.5.1366","article-title":"Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington\u2019s disease","volume":"50","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib130","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1212\/01.WNL.0000160388.96242.77","article-title":"High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study","volume":"64","author":"Tabrizi","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib131","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2032dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib132","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib133","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.20756","article-title":"CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington\u2019s disease","volume":"21","author":"Dubinsky","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.003_bib134","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial","volume":"65","author":"Puri","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib135","first-page":"34","article-title":"Lamotrigine does not retard the progression of Huntington\u2019s disease","author":"Kremer","year":"1997","journal-title":"WFN Working Group on Huntington\u2019s Disease"},{"key":"10.1016\/j.nurt.2008.01.003_bib136","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington\u2019s disease: a multicenter placebo-controlled study","volume":"61","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.003_bib137","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s004150170071","article-title":"Riluzole in Huntington\u2019s disease (HD): an open label study with one year follow up","volume":"248","author":"Seppi","year":"2001","journal-title":"J Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300555X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300555X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.01.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:43:05Z","timestamp":1761806585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792300555X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":137,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S187874792300555X"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.01.003","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotection for Huntington\u2019s Disease: Ready, Set, Slow","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}